Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Sberro-Soussan

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
British Medical Bulletin|October 26, 2017
The role of complement inhibition in kidney transplantationC Legendre, R Sberro-Soussan, J Zuber, et al.
Nephrologie & Therapeutique|November 13, 2008
[Screening biopsies in kidney transplantation: from subclinical acute rejection to chronic allograft lesions]R Snanoudj, F Martinez, R Sberro Soussan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 9, 2014
Risk of antibody-mediated rejection in kidney transplant recipients with anti-HLA-C donor-specific antibodiesO Aubert, M-C Bories, C Suberbielle, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 1, 2016
Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria DonorsY Le Meur, F Aulagnon, D Bertrand, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 15, 2013
Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changesG Canaud, N Kamar, D Anglicheau, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 4, 2010
Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodiesR Sberro-Soussan, J Zuber, C Suberbielle-Boissel, et al.
The New England Journal of Medicine|June 7, 2013
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndromeC M Legendre, C Licht, P Muus, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
British Medical Bulletin|October 26, 2017
The role of complement inhibition in kidney transplantationC Legendre, R Sberro-Soussan, J Zuber, et al.
Nephrologie & Therapeutique|November 13, 2008
[Screening biopsies in kidney transplantation: from subclinical acute rejection to chronic allograft lesions]R Snanoudj, F Martinez, R Sberro Soussan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 9, 2014
Risk of antibody-mediated rejection in kidney transplant recipients with anti-HLA-C donor-specific antibodiesO Aubert, M-C Bories, C Suberbielle, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 1, 2016
Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria DonorsY Le Meur, F Aulagnon, D Bertrand, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 15, 2013
Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changesG Canaud, N Kamar, D Anglicheau, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 4, 2010
Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodiesR Sberro-Soussan, J Zuber, C Suberbielle-Boissel, et al.
The New England Journal of Medicine|June 7, 2013
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndromeC M Legendre, C Licht, P Muus, et al.
Pageof 1